Table 1 Ongoing Selected Immunotherapy Trials in Bladder Cancer
Completed | ||
Drug/Agent | Study | Stage of Disease |
Atezolizumab (MPDL3280A) Anti-PD-L1 Cohort 1 NCT02951767, Cohort 2: NCT02108652 | Phase II | Locally advanced or metastatic – progressed after platinum-based treatment (Rosenberg et al. Lancet 2016; Balar et al. Lancet 2016 [63, 74]) |
Pembrolizumab NCT02256436 | Phase III vs. standard of care chemotherapy | Locally advanced or metastatic – progressed after platinum-based treatment |
Ongoing | ||
Drug/Agent | Study | Stage of Disease |
Durvalumab with or without tremelimumab NCT02516241 | Phase II vs. standard of care chemotherapy | Stage IV transitional cell carcinoma of the urothelium |
Atezolizumab NCT02662309 | Phase II preoperative MPDL3280A | Transitional cell carcinoma of the bladder |
Atezolizumab combination with cisplatin and gemcitabine NCT02989584 | Pilot safety, single-arm phase II study | Metastatic bladder cancer |
Atezolizumab NCT02450331 | Randomized phase III atezolizumab as adjuvant therapy vs. observation | PD-L1 positive, high risk muscle invasive bladder cancer |
Nivolumab NCT02632409 | Randomized phase III nivolumab as adjuvant therapy vs. placebo | High risk muscle-invasive bladder cancer |
Maintenance avelumab NCT02603432 | Phase III vs. best supportive care alone | Locally advanced or metastatic bladder cancer that did not progress after completion of first-line platinum containing chemotherapy |
Pembrolizumab NCT02335424 | Phase II | Non-cisplatin eligible patients |
MEDI-4736 (anti-PD-L1) +/− tremelimumab (anti-CTLA-4) NCT02516241 | Phase III, three arms: MEDI-4736 +/− tremelimumab vs. standard of care chemotherapy | Unresectable stage IV bladder cancer |